South-Island based medicinal cannabis company Medical Kiwi
has signed an exclusive distribution deal with United
Kingdom CBD product distributor Vitality CBD.
Established in December 2018, Medical Kiwi is a
medicinal research and nutraceutical company, created to
take advantage of the global opportunity that medicinal
cannabis represents. They are the only New Zealand company
to sign a distribution agreement with Vitality CDB Ltd.
The exclusive deal with the UK company will allow
Medical Kiwi to import and sell CBD products as soon as the
Medicinal Cannabis Scheme is operational in the first
quarter of 2020.
Medical Kiwi Board Chair Aldo Miccio
says the deal is an exciting step towards the company’s
plans to provide New Zealanders with affordable access to
safe, high-quality medicinal and neutraceutical cannabis
“Medical Kiwi will sell Vitality CBD’s
full range of CBD products, including sprays, drops, skin
cream, balms, and e-liquids. The range is currently sold
across the UK including in Boots stores, Tesco supermarkets,
pharmacies and health stores.”
The CBD products
contain cannabidiols derived from cannabis, and are 0% THC,
meaning they have no psychoactive properties.
“This agreement is part of Medical Kiwi’s strategy
to import and distribute pre-branded medicinal and
nutraceutical products, to create accessibility via imported
products until our own Medical Kiwi products are available,”
Last month the company announced its
plans for the build of a state-of-the-art research and
development facility in Brightwater, Tasman. They have been
granted a licence by the Ministry of Health to cultivate
medicinal cannabis, enabling the company to establish a
cannabis breeding programme for research.
of the 8,000 –10,000 m2 facility is set to start in late
2020. Its design aligns environmental responsibility with
commercial objectives, including technology to ensure
agricultural and commercial practices are sustainable.
Miccio says the facility and resulting products will
have significant economic benefits for the Nelson Tasman
region and for New Zealand. “Our research will focus on
the development of medicinal cannabis products, with a
particular focus on the optimum growth conditions,” he
Until the plant is operational, Medical Kiwi
will advance their vision of making medicinal cannabis
products available to New Zealanders by selling imported
product as soon as the law allows.
“Our business model
is for Medical Kiwi’s New Zealand-made and imported
products to cost significantly less than current
prescription prices,” says Miccio. “Once the Medicinal
Cannabis Scheme is in place, we will be able to share a lot
more about what that means.”
Miccio says Patrick
Gower’s documentary On Weed, debuting on TV3 on 11
September, demonstrated some of the major and important
benefits of medicinal cannabis.
“The documentary rightly
pointed out that the medicinal cannabis industry in New
Zealand is ready and waiting. Medical Kiwi is poised to make
our vision – that everyone who could benefit from
medicinal cannabis can safely access effective,
high-quality, affordable products – into reality.”
month, Medical Kiwi Ltd released an Investment Memorandum
for private professional investors, offering shares in
the company in two series.
“We raised $1 million
in seed funding from both private investors and investors
from the smart money sector in the US, who all recognise the
value of New Zealand-origin medicinal cannabis products,”
says Miccio. “We are now offering a new share issue to
raise $7.5 million, providing investors with an opportunity
to invest early in Series A. A Series B share offer will
follow later this year.”
The full scope of Medical
Kiwi’s operations from 2020 onwards will cover research
and development and cultivation, extraction, manufacturing,
supply and distribution, and marketing of medicinal and
nutraceutical cannabis products.
can be found on the Medical Kiwi website. www.medicalkiwi.com
and at www.facebook.com/MedicalKiwiNZ/. You can
find out more about Vitality CBD at https://vitalitycbd.co.uk/
© Scoop Media